Section 12.1: Non-Sterile Compounding Regulations
Key Takeaways
- Texas non-sterile compounding is governed under TSBP Rule §291.131, which closely aligns with the national USP <795> standards.
- Compounding (regulated under FDA Section 503A) must be patient-specific and is distinct from manufacturing (FDA Section 503B/registered manufacturers), which involves mass production for resale.
- Under the 2023 USP <795> revisions, beyond-use dates (BUDs) are determined by the preparation's water activity (aw), classifying formulations as nonaqueous (90 days), preserved aqueous (35 days), or non-preserved aqueous (14 days refrigerated).
- Texas requires all compounded prescriptions to carry a prominent label statement reading 'Compounded by Pharmacy' along with active ingredient names and strengths.
- Bulk compounding in anticipation of prescriptions is permitted under TSBP rules but only in limited quantities based on historically documented local prescribing patterns.
Section 12.1: Non-Sterile Compounding Regulations
Non-sterile compounding is regulated in Texas by the Texas State Board of Pharmacy (TSBP) under Texas Administrative Code (TAC) Rule §291.131, which mirrors USP Chapter <795> standards. Candidates preparing for the Texas MPJE must understand physical standards, operational rules, and beyond-use dating (BUD) principles.
Compounding vs. Manufacturing
A critical distinction under federal law and TSBP rules is the boundary between compounding and manufacturing. Under Section 503A, compounding is a customized service performed by a licensed pharmacist to meet a specific patient's needs. Under Section 503B, bulk production is classified as manufacturing:
- Section 503A (Traditional Compounding): Traditional pharmacies compound preparations for individual patients based on a valid, patient-specific prescription. Under 503A, pharmacies are regulated primarily by the state board (TSBP) and are exempt from FDA Current Good Manufacturing Practices (cGMP) and pre-market approval processes. The FDA retains inspection authority but generally defers to state boards for routine oversight.
- Section 503B (Outsourcing Facilities): Facilities compounding sterile preparations in bulk without patient-specific prescriptions register under 503B. They must comply with FDA cGMP, undergo FDA inspections, and may distribute compounds to practitioners for office use. In Texas, a 503B facility must hold a Class DSM pharmacy license.
- Anticipatory Compounding: Under TSBP rules, community pharmacies (Class A) may compound preparations in advance of receiving a prescription, but only in limited quantities based on historical prescribing patterns (typically not exceeding a 30-day supply). Compounding bulk quantities for resale or distribution to other pharmacies without patient-specific demand is classified as manufacturing and carries severe administrative penalties.
Physical Facility and Equipment Requirements
TSBP Rule §291.131 mandates specific facility and equipment standards to ensure quality control:
- Compounding Area: A designated area with adequate space must be set aside to prevent mix-ups and cross-contamination. It must be clean, well-lighted, and have accessible hand-washing facilities. The area must be separated from general dispensing areas by a barrier or partition if there is a risk of cross-contamination.
- Water Quality: Purified Water, USP (or better) is required for compounding non-sterile preparations when water is a component. Potable (tap) water is acceptable only for initial washing of equipment, but the final rinse must use Purified Water, USP to prevent chemical or microbial residues.
- Equipment: All equipment (balances, mortars, electronic mixers) must be clean, maintained, and calibrated. Balances must be calibrated at least annually by an qualified technician, with records kept for two years. Graduated cylinders and other measuring devices must meet appropriate class tolerances.
Ingredient Standards and the "Three-Year Receipt Rule"
Pharmacists compounding non-sterile preparations must use high-quality ingredients:
- Grade: Ingredients should preferably be USP/NF grade. If unavailable, analytical reagent or Food Chemicals Codex grade may be used. Industrial-grade chemicals are prohibited.
- COA: A Certificate of Analysis (COA) must be obtained and kept on file for each lot of bulk drug substances.
- Expiration Dates: If an ingredient lacks a manufacturer-assigned expiration date, the pharmacist must assign a conservative date based on stability data, not to exceed three years from the date of receipt at the pharmacy. The receipt date and assigned expiration must be written on the container.
Personnel Training and Competencies
All personnel engaged in compounding—including pharmacists, technicians, and trainees—must complete initial training in hand hygiene, garbing, equipment use, and documentation. The pharmacy must perform and document an initial competency assessment. The Pharmacist-in-Charge (PIC) must maintain records of all training and annual competency assessments for compounding personnel, immediately available for TSBP inspection.
Determining Beyond-Use Dates (USP <795> Revisions)
Under the 2023 USP <795> revisions adopted by the TSBP, BUDs are determined by the formulation type and the water activity ($a_w$) of the compounded non-sterile preparation. Water activity is a measure of free water available for microbial growth. Formulations with $a_w < 0.6$ are nonaqueous, while those with $a_w \geq 0.6$ are aqueous.
In the absence of formulation-specific stability data, the following maximum BUD limits must be applied to preparations packaged in tight, light-resistant containers:
| Formulation Type | Water Activity ($a_w$) | Storage Temperature | Maximum Beyond-Use Date (BUD) |
|---|---|---|---|
| Nonaqueous Oral Formulations (e.g., capsules, tablets, powders) | $< 0.6$ | Controlled Room Temp or Refrigerated | 90 Days |
| Nonaqueous Topical/Dermal (e.g., ointments, pastes) | $< 0.6$ | Controlled Room Temp or Refrigerated | 90 Days |
| Preserved Aqueous Formulations (e.g., oral suspensions with preservatives) | $\geq 0.6$ | Controlled Room Temp or Refrigerated | 35 Days |
| Non-Preserved Aqueous Formulations (e.g., suspensions without preservatives) | $\geq 0.6$ | Refrigerated ($2^{\circ}\text{C}$ to $8^{\circ}\text{C}$) | 14 Days |
Commercial Product Expirations
If a compounded preparation is prepared by manipulating a commercial product (such as crushing commercial tablets), the BUD assigned cannot exceed the manufacturer's original expiration date on the commercial container if it is shorter than the maximum BUD in the table.
Texas Labeling Requirements and Exam Traps
Under TSBP §291.131, every compounded preparation dispensed to a patient must carry standard labeling information, plus:
- Compounding Statement: A prominent label statement reading "Compounded by Pharmacy".
- Active Ingredients: The names and strengths of all active ingredients.
- Beyond-Use Date: The clearly stated assigned BUD.
- Storage Directions: Specific requirements (e.g., 'Keep Refrigerated').
MPJE Exam Trap: Flavoring
Under Texas law, adding flavoring to a commercially manufactured, FDA-approved product is classified as compounding. This requires a compounding record, assigning an appropriate BUD, and labeling the container with the statement "Compounded by Pharmacy". The pharmacist must ensure that the addition of flavoring does not compromise the stability of the drug product, and the product's original expiration date must be adjusted accordingly if it is shorter than 14 days refrigerated or 35 days room temp.
A pharmacist in a Texas Class A pharmacy receives a prescription for a customized pediatric oral suspension. The formulation is prepared using a commercially manufactured tablet, purified water, and an unpreserved simple syrup vehicle. If the manufacturer's tablets expire in one year, what is the maximum beyond-use date (BUD) that the pharmacist can assign to this preparation under current TSBP non-sterile compounding rules?
Which of the following is a specific labeling requirement under Texas State Board of Pharmacy rules for all compounded preparations dispensed directly to patients?
A pharmacy receives a bulk chemical container of an excipient used in non-sterile compounding. The manufacturer's label does not specify an expiration date. According to Texas pharmacy regulations, how should the pharmacist handle the expiration dating for this substance?